Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies
Authors' conclusion
RTX improved IMACS core set measures and had steroid sparing efficacy at 6 and 12 months in patients with IIM in this registry-based study.
Study context
- Population
- Patients with refractory idiopathic inflammatory myopathy (IIM) receiving rituximab (RTX) between 2018 and 2021 (F:M 29:13; mean age 39.5 years)F:M, 29:13
- Participants
- 42 patients
- Exposure
- RTX 1 g × two doses vs 500 mg × two doses; change from baseline
- 1 gn = 28
- 500 mgn = 14
- Outcome
- Short-term efficacy of RTX: total improvement score from IMACS core set measures
- Follow-up
- 6 months and 12 months
Main finding
As reported in the abstract
Mean (SD) improvement in total improvement score at 6 months
44.5
16
Mean (SD) improvement in total improvement score at 12 months
48.7
19.2
Observational data: associations, not effects.
Further findings
Manual muscle testing (MMT-8), physician global assessment (PGA), patient global assessment (PtGA) and median steroid dosage vs baseline · 6 and 12 months
- Improvement vs baseline in MMT-8, PGA, PtGA and median steroid dosage
- P < 0.01 for all
Change in MMT-8, PGA and PtGA from baseline, 1 g vs 500 mg · 6 and 12 months
- Comparable between the two dosage regimens
Safety
Severe lower respiratory tract infections requiring hospitalization
- Patients of the cohort
- 3
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →